Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of HC010 for Injection in the First-line Treatment of Advanced Non-small Cell Lung Cancer Positive for Programmed Death Ligand-1 (PD-L1)

NCT07169552 is registered in ClinicalTrials.gov with HC Biopharma Inc. as lead sponsor.

NCT NCT07169552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of HC010 for Injection in the First-line Treatment of Advanced Non-small Cell Lung Cancer Positive for Programmed Death Ligand-1 (PD-L1)
Lead sponsor
HC Biopharma Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 9, 2025
Completion date
September 30, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc